Molecular profiling to optimize treatment in non-small cell lung cancer: a review of potential molecular targets for radiation therapy by the translational research program of the radiation therapy oncology group.

@article{Ausborn2012MolecularPT,
  title={Molecular profiling to optimize treatment in non-small cell lung cancer: a review of potential molecular targets for radiation therapy by the translational research program of the radiation therapy oncology group.},
  author={Natalie L Ausborn and Quynh L{\^e} and Jeffrey D. Bradley and Hak Choy and Adam Dicker and Debabrata Saha and Jeff Simko and Michael D. Story and Artour Torossian and Bo Lu},
  journal={International journal of radiation oncology, biology, physics},
  year={2012},
  volume={83 4},
  pages={e453-64}
}
Therapeutic decisions in non-small cell lung cancer (NSCLC) have been mainly based on disease stage, performance status, and co-morbidities, and rarely on histological or molecular classification. Rather than applying broad treatments to unselected patients that may result in survival increase of only weeks to months, research efforts should be, and are being, focused on identifying predictive markers for molecularly targeted therapy and determining genomic signatures that predict survival and… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 21 extracted citations

Oncology scan--promising strategies for the treatment of locally-advanced non-small cell lung cancer.

International journal of radiation oncology, biology, physics • 2013
View 3 Excerpts
Highly Influenced

References

Publications referenced by this paper.
Showing 1-10 of 97 references

KRASmutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib

PaoW, WangTY, RielyGJ
PLoS Med • 2005
View 4 Excerpts
Highly Influenced

Principles and use of antiCTLA4antibody in human cancer.CurrOpin Immunol2006;16:206-213

KS Peggs, SA Quezada, AJ Korman
2006
View 3 Excerpts
Highly Influenced

Combination Chemotherapy, Radiation Therapy, and Bevacizumab in Treating Patients With Newly Diagnosed Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery

Southwest Oncology Group
[Cited • 2012

Comprehensive Cancer Center. Combination Chemotherapy, Bev, RT, and Erlotinib in Treating Patients With Stage III Non-Small Cell Lung Cancer

UNC Lineberger
[Cited • 2012

A phase I study of nab-paclitaxel (nP) with carboplatin (C) and thoracic radiation (TRT) in patients with locally advanced NSCLC.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology • 2011
View 1 Excerpt

Similar Papers

Loading similar papers…